Summit TherapeuticsSMMT
About: Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
Employees: 105
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
237% more first-time investments, than exits
New positions opened: 64 | Existing positions closed: 19
226% more capital invested
Capital invested by funds: $567M [Q2] → $1.85B (+$1.28B) [Q3]
100% more funds holding in top 10
Funds holding in top 10: 1 [Q2] → 2 (+1) [Q3]
43% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 35
34% more funds holding
Funds holding: 122 [Q2] → 163 (+41) [Q3]
1.33% more ownership
Funds ownership: 10.35% [Q2] → 11.68% (+1.33%) [Q3]
26% less call options, than puts
Call options by funds: $55.9M | Put options by funds: $75.5M
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
5 analyst ratings
Truist Securities Asthika Goonewardene 17% 1-year accuracy 4 / 24 met price target | 86%upside $35 | Buy Initiated | 8 Jan 2025 |
Wells Fargo Mohit Bansal 29% 1-year accuracy 7 / 24 met price target | 59%upside $30 | Overweight Initiated | 11 Dec 2024 |
Jefferies Brent Thill 69% 1-year accuracy 37 / 54 met price target | 65%upside $31 | Buy Initiated | 6 Dec 2024 |
HC Wainwright & Co. Mitchell Kapoor 27% 1-year accuracy 45 / 164 met price target | 134%upside $44 | Buy Reiterated | 18 Nov 2024 |
JMP Securities Reni Benjamin 8% 1-year accuracy 3 / 36 met price target | 70%upside $32 | Market Outperform Initiated | 4 Nov 2024 |
Financial journalist opinion
Based on 10 articles about SMMT published over the past 30 days